US Broker Ratings

Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: A Biotech with 134% Upside Potential

Zevra Therapeutics, Inc. (NASDAQ: ZVRA), a commercial-stage biotechnology firm, has captured the attention of investors with its significant growth potential and promising pipeline focused on rare diseases. With a market..

Fulgent Genetics, Inc. (FLGT) Stock Analysis: Unveiling a 15.65% Potential Upside in the Dynamic Diagnostics Sector

Fulgent Genetics, Inc. (NASDAQ: FLGT), a prominent player in the Healthcare sector, stands out with a compelling 15.65% potential upside according to recent analyst ratings. Specializing in Diagnostics & Research,..

Simulations Plus, Inc. (SLP): Investor Outlook Highlights a 111.74% Potential Upside

Simulations Plus, Inc. (SLP), a prominent player in the healthcare sector, is grabbing the attention of investors with a substantial 111.74% potential upside according to recent analyst ratings. Specializing in..

Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis: Unveiling a 32.91% Potential Upside

Xeris Biopharma Holdings, Inc. (NASDAQ: XERS) presents an intriguing case for investors with a compelling 32.91% potential upside based on the current average target price of $6.30. Operating within the..

iRadimed Corporation (IRMD) Stock Analysis: Potential 16.95% Upside Beckons Investors

iRadimed Corporation (NASDAQ: IRMD), a leading player in the healthcare sector with a focus on medical devices, presents a compelling investment opportunity for individual investors. Headquartered in Winter Springs, Florida,..

HealthStream, Inc. (HSTM) Stock Analysis: Navigating Growth with a 26% Upside Potential

HealthStream, Inc. (NASDAQ: HSTM), a Nashville-based company specializing in health information services, is generating buzz among investors and analysts alike. With a market capitalization of $833.04 million and a focus..

uniQure N.V. (QURE) Stock Analysis: Exploring a 155% Potential Upside in the Biotech Sector

uniQure N.V. (NASDAQ: QURE) stands as a compelling opportunity within the biotechnology sector, a niche renowned for its high risk and potentially high rewards. With a market capitalization of $779.07..

KalVista Pharmaceuticals, Inc. (KALV)

⚠️ No article content returned.

..

Mind Medicine (MNMD) Stock Analysis: Exploring a 263.50% Potential Upside in the Biotech Sector

Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is capturing the attention of investors with its ambitious approach to tackling brain health disorders and an impressive 263.50% potential upside. Operating within the..

Tyra Biosciences, Inc. (TYRA) Stock Analysis: Exploring a Promising 206% Upside with Strong Buy Ratings

Tyra Biosciences, Inc. (TYRA), a clinical-stage biotechnology company, stands out in the healthcare sector with a market capitalization of $522.74 million. As an innovative player in the biotechnology industry, Tyra..

Owens & Minor, Inc. (OMI)

⚠️ No article content returned.

..

Auna SA (AUNA) Stock Analysis: Healthcare Leader with a 99% Upside Potential

For investors eyeing opportunities in the healthcare sector, Auna S.A. (AUNA) presents a compelling case. Operating hospitals and clinics across Mexico, Peru, and Colombia, Auna is a notable player in..

Neuropace, Inc. (NPCE) Stock Analysis: A 56% Potential Upside Awaits Investors

Neuropace, Inc. (NPCE), a trailblazer in the healthcare sector, specifically within the medical devices industry, stands out with its innovative approach to treating drug-resistant focal epilepsy. The company, headquartered in..

Rocket Pharmaceuticals, Inc. (RCKT) Stock Analysis: Eyeing a 248.78% Potential Upside in the Biotech Sector

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a promising player in the biotechnology sector, is capturing investor attention with a staggering potential upside of 248.78%. As a late-stage biotech firm headquartered in..

Praxis Precision Medicines, Inc (PRAX) Stock Analysis: Unlocking 121.77% Potential Upside in Biotechnology

Praxis Precision Medicines, Inc (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, has been gaining attention in the biotechnology sector with its focus on developing therapies for central nervous system (CNS) disorders...

Arbutus Biopharma (ABUS) Investor Outlook: Unpacking a Potential 67% Upside in the Healthcare Innovator

Arbutus Biopharma Corporation (NASDAQ: ABUS) has positioned itself as a noteworthy contender in the biotechnology sector, with a specific focus on developing innovative treatments for infectious diseases. Headquartered in Warminster,..

Community Health Systems, Inc. (CYH) Stock Analysis: Navigating Healthcare with a 21% Upside Potential

Community Health Systems, Inc. (NYSE: CYH), a prominent player in the U.S. healthcare sector, is currently capturing investor attention with its intriguing mix of performance metrics and potential upside. Operating..

LENZ Therapeutics, Inc. (LENZ) Stock Analysis: Biotechnology’s Visionary with 47.79% Potential Upside

Investors with an eye for promising biotech ventures may find LENZ Therapeutics, Inc. (NASDAQ: LENZ) a compelling addition to their portfolios. This Solana Beach-based company is making waves in the..

Immatics N.V. (IMTX) Stock Analysis: Exploring a 156% Potential Upside in the Biotech Arena

Immatics N.V. (NASDAQ: IMTX) stands at a pivotal juncture in the biotechnology sector, capturing investor attention with a potential upside of 156.41%. Specializing in the development of T cell redirecting..

Embecta Corp. (EMBC): Investor Outlook on a 91% Potential Upside

Embecta Corp. (NASDAQ: EMBC), a key player in the healthcare sector, is capturing the attention of investors with its significant potential upside of 91.27%. Specializing in medical instruments and supplies,..

US Broker Ratings

US Broker Ratings

FTSE 100

Funds